文献速递肝病消化道肿瘤与早癌

非酒精性脂肪性肝炎肝移植的结局:欧洲肝移植登记研究

Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study.
PubMed 文献 · J Hepatol · 2019-05-07

该研究基于欧洲肝移植登记数据库,分析2002年1月至2016年12月因终末期肝病行首次肝移植的68,950例成人数据,比较非酒精性脂肪性肝炎(NASH)与其他病因的结局。NASH肝移植比例从2002年1.2%升至2016年8.4%,NASH患者肝细胞癌比例更高(39.1% vs 28.9%,p<0.001),但校正变量后NASH与患者及移植物生存无显著关联。

要点

  • NASH肝移植比例从2002年1.2%增至2016年8.4%,总体占4.0%。
  • NASH患者肝细胞癌比例为39.1%,高于非NASH患者的28.9%(p<0.001)。
  • 校正变量后NASH与患者生存(HR 1.02,p=0.713)及移植物生存(HR 0.99,p=0.815)无显著关联。

核心结论

  • 2002年至2016年间欧洲因NASH行肝移植的数量和比例增加。
  • NASH患者肝细胞癌更常见,但患者和移植物生存与其他疾病指征相当。

研究设计与样本

  • 分析欧洲肝移植登记数据库2002年1月至2016年12月因终末期肝病行首次肝移植的成人数据,比较NASH与其他病因,主要终点为患者和整体移植物生存。

主要发现

  • 68,950例成人首次肝移植中4.0%因NASH移植,比例从2002年1.2%增至2016年8.4%。
  • NASH患者肝细胞癌比例为39.1%,非NASH患者为28.9%(p<0.001)。
  • 校正可获得的受者和供者变量后,NASH与患者生存(HR 1.02,p=0.713)及移植物生存(HR 0.99,p=0.815)无显著关联。
  • 无肝细胞癌的NASH患者常见死因为感染(24.0%)和心脑血管并发症(5.3%)。
  • 无肝细胞癌的NASH患者中,受者年龄61-65岁(HR 2.07,p<0.001)、>65岁(HR 1.72,p=0.017)、MELD评分>23(HR 1.48,p=0.048)、体重指数<18.5 kg/m2(HR 4.29,p=0.048)或>40 kg/m2(HR 1.96,p=0.012)独立预测死亡。

临床怎么用

  • 作者指出需要仔细评估危险因素,以维持NASH患者良好的移植后结局。

局限性

  • 数据必须在缺乏公认混杂因素(如病前代谢危险因素)的背景下解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Little is known about outcomes of liver transplantation for patients with non-alcoholic steatohepatitis (NASH). We aimed to determine the frequency and outcomes of liver transplantation for patients with NASH in Europe and identify prognostic factors. METHODS: We analysed data from patients transplanted for end-stage liver disease between January 2002 and December 2016 using the European Liver Transplant Registry database. We compared data between patients with NASH versus other aetiologies. The principle endpoints were patient and overall allograft survival. RESULTS: Among 68,950 adults undergoing first liver transplantation, 4.0% were transplanted for NASH - an increase from 1.2% in 2002 to 8.4% in 2016. A greater proportion of patients transplanted for NASH (39.1%) had hepatocellular carcinoma (HCC) than non-NASH patients (28.9%, p <0.001). NASH was not significantly associated with survival of patients (hazard ratio [HR] 1.02, p = 0.713) or grafts (HR 0.99; p = 0.815) after accounting for available recipient and donor variables. Infection (24.0%) and cardio/cerebrovascular complications (5.3%) were the commonest causes of death in patients with NASH without HCC. Increasing recipient age (61-65 years: HR 2.07, p <0.001; >65: HR 1.72, p = 0.017), elevated model for end-stage liver disease score (>23: HR 1.48, p = 0.048) and low (<18.5 kg/m2: HR 4.29, p = 0.048) or high (>40 kg/m2: HR 1.96, p = 0.012) recipient body mass index independently predicted death in patients transplanted for NASH without HCC. Data must be interpreted in the context of absent recognised confounders, such as pre-morbid metabolic risk factors. CONCLUSIONS: The number and proportion of liver transplants performed for NASH in Europe has increased from 2002 through 2016. HCC was more common in patients transplanted with NASH. Survival of patients and grafts in patients with NASH is comparable to that of other disease indications. LAY SUMMARY: The prevalence of non-alcoholic fatty liver disease has increased dramatically in parallel with the worldwide increase in obesity and diabetes. Its progressive form, non-alcoholic steatohepatitis, is a growing indication for liver transplantation in Europe, with good overall outcomes reported. However, careful risk factor assessment is required to maintain favourable post-transplant outcomes in patients with non-alcoholic steatohepatitis.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Haldar D, Kern B, Hodson J, et al. Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study. J Hepatol. 2019. PMID: 31071367. doi:10.1016/j.jhep.2019.04.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。